Abstract
role of this gene in the development of type 2 diabetes has yet to be determined, but TCF7L2 is known to control the activity of a number genes, including the proglucagon gene, which encodes the insulinotropic hormone glucagon-like peptide 1 (GLP-1). GLP-1, along with insulin, plays a role in blood glucose homeostasis, and GLP-1-based therapies for type 2 diabetes are currently in clinical development (Bloomgarden ZT. Diabetes Care. 2004;27:2554-2559). Stefansson and other researchers hope to reveal TCF7L2’s mechanism of action and identify potential targets for drugs that could be used to treat individuals who have or are at risk for developing type 2 diabetes because of this gene variant. “We’ll try to replicate the findings and there will probably be lots of other groups doing the same thing,” said Cox, adding “I’m sure this pathway will receive a lot more attention in diabetes research.”
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call